A SINGLE-DOSE, UNCONTROLLED, OPEN LABEL, NON-RANDOMIZED, CLINICAL PHARMACOLOGY STUDY OF CHF 5993 100/6/12.5 μg PMDI (FIXED COMBINATION OF BECLOMETASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE PLUS GLYCOPYRRONIUM BROMIDE) IN ASTHMATIC ADOLESCENT PATIENTS AND ADULT PATIENTS
Latest Information Update: 23 Feb 2023
At a glance
- Drugs Beclometasone/formoterol/glycopyrrolate (Primary)
- Indications Asthma
- Focus Pharmacodynamics
- Sponsors Chiesi Farmaceutici SpA
Most Recent Events
- 13 May 2021 This trial has been completed in Poland, according to European Clinical Trials Database
- 13 Feb 2020 New trial record